Evaluation of tigecycline in vitro activity against panresistant Klebsiellapneumoniae clinical isolates
Abstract number: 1733_1535
Stylianakis A., Koutsoukou A., Tsiplakou S., Garavella V., Taxtatzis M., Merianos I.
Objectives: The purpose of our study was to evaluate the in vitro activity of tigecycline against panresistant Klebsiellapneumoniae clinical isolates.
Methods: We examined 68 non duplicated panresistant Klebsiellapneumoniae isolates recovered from blood cultures, bronchoalveolar excretions and pus and urine samples derived from ICU-patients of our hospital during a one year-time period. The identification of the isolates and the susceptibility testing were performed by the automated VITEK 2 system (boiMérieux, France). The susceptibility testing for tigecycline was performed by Kirby-Bauer disk diffusion method and done by direct colony suspension according to CLSI guidelines. Paper disks containing tigecycline at 15 mg per disk were used (Becton-Dickinson, USA). The determination of tigecycline-MIC values was performed by E-test strips according to the manufacturer's guidelines (AB-Biodisk, Sweden). Isolates with an inhibition zone diameter of ≥ 19 mm and with an MIC level ≤ 1 mg/L were considered as susceptible to tigecycline (MIC-susceptibility limits determined by EUCAST).
Results: All the Klebsiellapneumoniae clinical isolates were resistant to aminoglycosides, b-lactams, carbapenems, monobactames, furanes, cinolones and colistin. The tigecycline was found absolute active to all the examined isolates. The inhibition diameter zones were found of ≥ 21 mm and the MIC levels of ≤0.5 mg/L
Conclusion: Tigecycline is absolute active to panresistant Klebsiellapneumoniae isolates and holds great promise as a therapeutic agent to combat or limit desperate infections caused by these panresistant isolates.
|Session name:||European Society of Clinical Microbiology and Infectious Diseases|
|Location:||ICC, Munich, Germany|
|Back to top|